Development of a preclinical model of myeloid tumors with high immune checkpoints expression

Background. Myelodysplastic syndrome is a group of malignant blood diseases with a high risk of transformation into acute myeloid leukemia. One treatment approach is to target immune checkpoints (ICs) that are overexpressed on tumor cells. To develop these drugs, relevant models are needed for highthroughput screening and study of these biologically active substances, since traditionally used models (mouse and patient biomaterials) are difficult to access, financially and laborintensive, and are characterized by poorly reproducible results.

Aim. To develop a model based on a human myeloid cell line with increased expression of L1 and TIM3 to study the activity of ICs inhibitors, the presence of which in the tumor microenvironment in patients with myelodysplastic syndrome and acute myeloid leukemia was associated with a high risk and worse prognosis.

Materials and methods. Initial testing of the L1 and TIM3 basal expression level was carried out on cell lines: TH1, HL60, OCIAML2, OCIAML5, KG1, MonoMac1. Induction of IC expression was carried out using interferon γ. Analysis of marker expression was carried out 24 hours after induction of ICs expression and addition of MK2206 using flow cytometry.

Results. Basal expression of the studied ICs receptors was absent in all of them, except for KG1; TIM3 was present in 88.4 ± 7.1 % of cells, and L1 – in 88 ± 8.5 %. The addition of interferon γ at a concentration of 50 ng/mL to the MonoMac1 culture led to a significant increase in the proportion of TIM3 and L1 expressing cells (53.3 ± 12.2 and 97.3 ± 1.1 % respectively, compared to 0.1 ± 0.1 and 0.1 ± 0.1 % without interferon γ), and for TH1 only L1 expression (87.5 ± 20 %, control 0.1 ± 0.1 %) was observed at the concentration of interferon γ in a medium of 50 ng/mL, while the proportion of cells expressing TIM3 was 6.9 ± 10 % (control 0.1 ± 0.1 %).

Conclusion. The KG1 line, which constantly expresses significant levels of target ICs, as well as TH1 and MonoMac1, which are induced by 50 ng/mL interferon γ, were selected as a model with increased L1 and TIM3 expression based on a human myeloid cell line. The model efficiency was confirmed by the rational response to the IC pathway inhibitor.

1. Chen H., Wang M., Weng T. et al. The prognostic and clinicopathological significance of Tim3 and PD1 expression in the prognosis of upper urinary tract urothelial carcinoma. Urol Oncol 2021;39(11):743–53. DOI: 10.1016/j.urolonc.2021.05.039

2. Kouroukli O., Symeonidis A., Foukas P. et al. Bone marrow immune microenvironment in myelodysplastic syndromes. Cancers (Basel) 2022;14(22):5656. DOI: 10.3390/cancers14225656

3. Yang H., BuesoRamos C., DiNardo C. et al. Expression of PDL1, PDL2, PD1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia 2014;28(6):1280–8. DOI: 10.1038/leu.2013.355

4. Kondo A., Yamashita T., Tamura H. et al. Interferongamma and tumor necrosis factoralpha induce an immunoinhibitory molecule, B7H1, via nuclear factorkappaB activation in blasts in myelodysplastic syndromes. Blood 2010;116(7):1124–31. DOI: 10.1182/blood200912255125

5. Ai L., Chen J., Yan H. et al. Research status and outlook of PD1/ PDL1 inhibitors for cancer therapy. Drug Des Devel Ther 2020;14:3625–49. DOI: 10.2147/DDDT.S267433

6. Yi M., Zheng X., Niu M. et al. Combination strategies with PD1/ PDL1 blockade: current advances and future directions. Mol Cancer 2022;21(1):28. DOI: 10.1186/s12943021014892

7. Yang X., Ma L., Zhang X. et al. Targeting PD1/PDL1 pathway in myelodysplastic syndromes and acute myeloid leukemia. Exp Hematol Oncol 2022;11(1):11. DOI: 10.1186/s40164022002634

8. Jan M., Chao M.P., Cha A.C. et al. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci USA 2011;108(12):5009–14. DOI: 10.1073/pnas.1100551108

9. Zhang L., Du H., Xiao T.W. et al. Prognostic value of PD1 and TIM3 on CD3+ T cells from diffuse large Bcell lymphoma. Biomed Pharmacother 2015;75:83–7. DOI: 10.1016/j.biopha.2015.08.037

10. Kikushige Y., Shima T., Takayanagi S. et al. TIM3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell 2010;7(6):708–17. DOI: 10.1016/j.stem.2010.11.014

11. Tcvetkov N., Gusak A., Morozova E. et al. Immune checkpoints bone marrow expression as the predictor of clinical outcome in myelodysplastic syndrome [published correction appears in Leuk Res Rep 2022;17:100301]. Leuk Res Rep 2020;14:100215. DOI: 10.1016/j.lrr.2020.100215

12. Ma S., Tian Y., Peng J. et al. Identification of a smallmolecule TIM3 inhibitor to potentiate T cellmediated antitumor immunotherapy in preclinical mouse models. Sci Transl Med 2023;15(722):eadg6752. DOI: 10.1126/scitranslmed.adg6752

13. Abaza Y., Zeidan A.M. Immune checkpoint inhibition in acute myeloid leukemia and myelodysplastic syndromes. Cells 2022;11(4):2249. DOI: 10.3390/cells11142249

14. Grenga I., Donahue R.N., Lepone L. et al. PDL1 and MHCI expression in 19 human tumor cell lines and modulation by interferongamma treatment. J Immunother Cancer 2014;2(Suppl 3):P102. DOI: 10.1186/205114262S3P102

15. Imai Y., Chiba T., Kondo T. et al. Interferon¬γ induced PD¬L1 expression and soluble PD¬L1 production in gastric cancer. Oncol Lett 2020;20(3):2161–8. DOI: 10.3892/ol.2020.11757

16. Spangenberg S.H., Zavareh R.B., Lairson L.L. Protocol for high throughput compound screening using flow cytometry in THP1 cells. STAR Protoc 2021;2(2):100400. DOI: 10.1016/j.xpro.2021.100400

17. Thiem A., Hesbacher S., Kneitz H. et al. IFNgammainduced PDL1 expression in melanoma depends on p53 expression. J Exp Clin Cancer Res 2019;38(1):397. DOI: 10.1186/s1304601914039

18. Wang F., Yang L., Xiao M. et al. PDL1 regulates cell proliferation and apoptosis in acute myeloid leukemia by activating PI3KAKT signaling pathway. Sci Rep 2022;12(1):11444. DOI: 10.1038/s41598022150200

19. Mujib S., Jones R.B., Lo C. et al. Antigenindependent induction of Tim3 expression on human T cells by the common γchain cytokines IL2, IL7, IL15, and IL21 is associated with proliferation and is dependent on the phosphoinositide 3kinase pathway. J Immunol 2012;188(8):3745–56. DOI: 10.4049/jimmunol.1102609

20. Rezaei M., Ghanadian M., Ghezelbash B. et al. TIM3/Gal9 interaction affects glucose and lipid metabolism in acute myeloid leukemia cell lines. Front Immunol 2023;14:1267578. DOI: 10.3389/fimmu.2023.1267578

21. SriNgernNgam K., Keawvilai P., Pisitkun T., Palaga T. Upregulation of programmed cell death 1 by interferon gamma and its biological functions in human monocytes. Biochem Biophys Rep 2022;32:101369. DOI: 10.1016/j.bbrep.2022.101369

22. Shapourian H., Ghanadian M., Eskandari N. et al. TIM3/ Galectin9 interaction and glutamine metabolism in AML cell lines, HL60 and THP1. BMC Cancer 2024;24(1):125. DOI: 10.1186/s12885024118983

23. Gonçalves Silva I., Rüegg L., Gibbs B.F. et al. The immune receptor Tim3 acts as a trafficker in a Tim3/galectin9 autocrine loop in human myeloid leukemia cells. Oncoimmunology 2016;5(7):e1195535. DOI: 10.1080/2162402X.2016.1195535

24. Xing Y., Lin N.U., Maurer M.A. et al. Phase II trial of AKT inhibitor MK2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/ PTEN mutation. Breast Cancer Res 2019;21(1):78. DOI: 10.1186/s1305801911548